文献速递造血干细胞移植与细胞治疗

HLA-B前导序列遗传变异评估工具及其临床移植意义

Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation.
PubMed 文献 · Blood Adv · 2022-01-01

Sequence variation in the HLA-B gene is critically linked to differential immune responses. A dimorphism at -21 of HLA-B exon 1 gives rise to leader peptides that are markers for risk of acute graft-versus-host disease, relapse, and mortality after unrelated donor and cord blood …

要点

  • BLEAT可自动化判定HLA-B前导基因型并排序候选干细胞来源的临床风险。
  • HLA-B外显子1的-21位二态性影响无关供者及脐血移植后aGVHD、复发和死亡风险。

核心结论

  • BLEAT可用于优化基于HLA-B前导序列的干细胞移植来源选择,并广泛用于基础与临床研究。

研究设计与样本

  • 在第二队列1259例患者及其无关移植供者中评估前导序列判定的准确性。

主要发现

  • HLA-B外显子1的-21位二态性产生的前导肽是无相关供者及脐血移植后急性移植物抗宿主病、复发和死亡风险的标志物。
  • BLEAT可自动化判定前导基因型、定义HLA-B前导序列匹配状态并按临床风险排序候选干细胞来源。

临床怎么用

  • 可用于根据HLA-B前导序列选择最佳干细胞移植来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sequence variation in the HLA-B gene is critically linked to differential immune responses. A dimorphism at -21 of HLA-B exon 1 gives rise to leader peptides that are markers for risk of acute graft-versus-host disease, relapse, and mortality after unrelated donor and cord blood transplantation. To optimize the selection of stem cell transplant sources based on the HLA-B leader, an HLA-BLeader Assessment Tool (BLEAT) was developed to automate the assignment of leader genotypes, define HLA-B leader match statuses, and rank order candidate stem cell sources according to clinical risk. The base cohort consisted of 9 417 614 registered donors from the Be The Match Registry with HLA-B typing. Among these donors, the performance of BLEAT was assessed in 1 098 358 donors with sequence data for HLA-B exon 1 (2 196 716 haplotypes). The accuracy of leader assignment was then assessed in a second cohort of 1259 patients and their unrelated transplant donors. We furthermore established the frequencies of HLA-B leader genotype (MM, MT, TT) representations in broad racial categories in the 9.42 million donors. BLEAT has direct applications for the selection of optimal stem cell sources for transplantation and broad utility in basic and clinical research in pharmacogenomics, vaccine development, and cancer and infectious disease studies of human populations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sajulga R, Bolon YT, Maiers MJ, et al. Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation. Blood Adv. 2022. PMID: 34529780. doi:10.1182/bloodadvances.2021004561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。